JNJ-64407564 is a bispecific antibody that targets CD3, which is expressed on T-cells, and GPRC5D, which is highly expressed in multiple myeloma cells. JNJ-64407564 was created under a collaboration between Genmab and Janssen Biotech, Inc. using Genmab's DuoBody® technology. 

Clinical studies
JNJ-64407564 is being investigated in a Phase I clinical study to treat relapsed or refractory multiple myeloma.